Navigation Links
Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
Date:6/26/2008

LONDON, June 26 /PRNewswire/ -- Duke University Medical Center has licensed ALPHADAS(R) Logos Technologies electronic data capture (EDC) software to accelerate and streamline its early-phase clinical trials and to enable physicians to follow patients more closely.

Researchers at Duke, which will become the first academic medical center in the country to use the ALPHADAS system, believe the technology has the potential to be a more accurate, real-time system that may improve the safety of clinical trial participants and contribute to more timely development of new drugs.

The agreement was announced today at the 44th annual Drug Information Association meeting in Boston.

"We will be using this innovative system in our two clinical research units as well as in our new, 30-bed Phase I Duke Clinical Research Unit (DCRU)," said Robert M. Califf, MD, director of the Duke Translational Medicine Institute and vice chancellor for clinical research at the Duke University School of Medicine. "The Phase I trial program here will become the hub of our efforts in translational science. It's where we will do some of our most exciting work, which will focus on proof-of-concept studies evaluating the impact of new therapies on human systems biology."

Duke will pay for the project through support from the Clinical and Translational Science Award, a five-year, $53 million grant from the National Institutes of Health awarded to Duke in 2006. The grant is intended to transform how clinical and translational research is conducted, and enabling researchers to develop new treatments faster and deliver them to patients more efficiently and quickly.

Barry Mangum, PharmD, FCP, director of clinical pharmacology for the DCRU and associate clinical professor of clinical pharmacology at Duke University Medical Center, says the proprietary ALPHADAS software will run on the DCRU's computer system to capture, integrate and report on clinical data in real-time
'/>"/>

SOURCE Logos Technologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
3. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
4. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
5. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
6. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
7. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
8. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
9. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
10. Senesco Technologies Initiates Preclinical Studies for Cancer Target
11. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 Depomed, Inc. (Nasdaq: ... offer, subject to market and other conditions, $230 million ... (the "Notes"). Depomed, Inc. ("Depomed") expects to grant the ... up to an additional $34.5 million aggregate principal amount ... RBC Capital Markets, LLC will act as joint book-running ...
(Date:9/2/2014)... signs monitoring devices market with over 40% market share, ... American and European vital signs monitors markets is expected ... the end of 2013. They have been driving the ... people across these economies. The European market is expected ... rising demand for home health patient monitoring devices due ...
(Date:9/2/2014)... YORK , Sept. 2, 2014 ... is available in its catalogue: Acute ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... 2014 Summary GlobalData,s clinical trial ... H2, 2014" provides data on the Acute Heart ...
Breaking Medicine Technology:Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 2Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 3Market of Vital Signs Monitoring Devices Forecast to 2018 2Market of Vital Signs Monitoring Devices Forecast to 2018 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... 2007 - Lux Biosciences,Inc., a privately held biotechnology ... today that the company's,next-generation calcineurin inhibitor, LX211, is ... Research in Vision and,Ophthalmology (ARVO) annual meeting, being ... an oral presentation being given on May 5 ...
... at 59th American Academy of Neurology Annual Meeting, ... /PRNewswire/ --,PTC Therapeutics, Inc. (PTC), a biopharmaceutical company ... targeting,post-transcriptional control processes, today announced positive,interim data from ... patients,with Duchenne muscular dystrophy (DMD) due to a ...
Cached Medicine Technology:Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 2Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 3Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 4PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 4PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 5
(Date:9/3/2014)... An inspiring story of the importance ... the season finale of “Extreme Weight Loss” Season Four. ... daughter from Highlands Ranch, Colo. who have a strained ... pounds. Their challenge is to team up to lose ... non-competitive approach to weight loss transformations, “Extreme Weight Loss” ...
(Date:9/3/2014)... 03, 2014 Health information technology ... safety, decreases medical errors, and strengthens the interaction ... mark the important role health information technology plays ... others across the U.S. have joined together to ... September 16-20, 2014. With the NHIT Week theme: ...
(Date:9/3/2014)... (PRWEB) September 03, 2014 Independent ... use of appropriate evidence-based health care along the ... benefit from the expertise of accredited independent review ... health care system. , As a core function, ... often settle questions of medical necessity. Yet backed ...
(Date:9/2/2014)... IMCA Speedway Motors Super Nationals, presented by Casey’s ... at the IMCA Speedway in Boone, Iowa. On ... check presentation to Hope For The Warriors® ( http://www.hopeforthewarriors.org ... organization that assists post-9/11 service members, their families, and ... psychological wounds in the line of duty. ...
(Date:9/2/2014)... PULLMAN, Wash. - Smoking today,s concentrated pot might ... research from Washington State University. The study is ... development of tolerance to THC. , Psychology ... estrogen levels, female rats are at least 30 ... qualities of THCthe key active ingredient in cannabis. ...
Breaking Medicine News(10 mins):Health News:“Extreme Weight Loss”: Jeff and Juliana’s Journey begin at the University of Colorado Anschutz Health and Wellness Center 2Health News:Innovative Healthcare Solutions (IHS) Celebrates National Health IT Week September, 15-19, 2014 2Health News:Independent Review Expands Its Scope: Case Studies in Context 2Health News:Independent Review Expands Its Scope: Case Studies in Context 3Health News:IMCA to Present Donation to Hope For The Warriors 2Health News:Estrogen increases cannabis sensitivity 2Health News:Estrogen increases cannabis sensitivity 3
... , , ATLANTA, ... related to the diagnosis and treatment of infertility with ovulation induction ... emotional, scientific and financial aspects. Discussions include information about age related ... donor sperm or donor eggs. , , ...
... , , ... officials announced today that Tennessee residents have saved over $7.3 million ... the free statewide prescription assistance program. Tennessee Drug Card, which ... 2007. The program has no restrictions to membership, no income requirements, ...
... , , MINNEAPOLIS, July 27 ... world,s population, often resulting in patches of dry skin, and little red ... the teenage years but may continue throughout adulthood. There is no ... B. Fleischer, professor and chair of the department of dermatology at Wake ...
... exercise at lower concentrations , MONDAY, July 27 (HealthDay ... have a negative effect on lung function in healthy people, ... allows for ozone concentrations of up to 75 parts per ... that 6.6 hours exposure to mean ozone concentrations as low ...
... , LA JOLLA, Calif., July 27 For the ... business leaders, community members and cancer survivors "surfing for a cure" ... held at UC San Diego,s Scripps Institution of Oceanography. Now, members ... Longboard Invitational portion of the event that takes place on Sunday, ...
... New York, NY The Lymphoma Research Foundation (LRF) is ... Research Foundation Clinical Investigator Career Development Award has been ... the Nebraska Medical Center in Omaha, Nebraska. ... is broadly categorized into Hodgkin lymphoma (HL) and non-Hodgkin ...
Cached Medicine News:Health News:Tennessee Drug Card Has Saved Residents Over $7.3 Million 2Health News:What Is Keratosis Pilaris (KP)? 2Health News:'Safe' Ozone Levels May Not Be for Some 2Health News:Moores UCSD Cancer Center Luau & Longboard Invitational Celebrates 16 Years of 'Surfing for a Cure' to Raise Funds for Cancer Research 2Health News:Moores UCSD Cancer Center Luau & Longboard Invitational Celebrates 16 Years of 'Surfing for a Cure' to Raise Funds for Cancer Research 3Health News:Moores UCSD Cancer Center Luau & Longboard Invitational Celebrates 16 Years of 'Surfing for a Cure' to Raise Funds for Cancer Research 4Health News:Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research 2
... Insulin-like growth factor II (IGF-II) is a ... the liver and is postulated to have mitogenic ... actions of IGF-II are mediated by binding to ... to the Type II IGF receptor, a monomeric ...
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
... proteohormone with a molecular weight of 16 kDa. ... and produced by adipocytes [1,2]. Leptin is thought ... body weight [1-3]. In the human, leptin levels ... women [4]. A relationship between serum leptin levels ...
... known as Anti-Mullerian Inhibiting Substance (AMH), is ... kDa monomers linked by disulfide bridges (1). ... (TGF-?) superfamily which includes TGF-? and the ... members of this superfamily are dimeric glycoproteins, ...
Medicine Products: